

Measure Concept		De-escalation of Anti-MRSA Antibiotics
Description		Percentage of patients with empiric anti-MRSA antibiotics discontinued when no resistant <i>Staphylococcus aureus</i> isolates are present in site specific cultures or molecular tests
<input type="checkbox"/> Established/Endorsed Measure	Source	
	Link	
Measure Specifications		
Type <input type="checkbox"/> Outcome <input checked="" type="checkbox"/> Process <input type="checkbox"/> Structure	Numerator	Number of denominator eligible patients whose anti-MRSA antibiotics were discontinued at or before 72 hours-of antibiotic start
	Denominator	<p>Inpatients with site-specific cultures or molecular tests negative for MRSA and the RxNorm Code for an Anti-MRSA antibiotic during the encounter</p> <p>Definitions (for the purposes of this measure):</p> <p>Site specific –blood, cerebrospinal fluid, pleural fluid, pericardial fluid, peritoneal fluid, joint/synovial fluid, bone, internal body sites (e.g., lymph node, brain, heart, liver, spleen, vitreous fluid, kidney, pancreas, lung, or ovary), nasal, nasopharyngeal, sputum.</p> <p>Anti-MRSA antibiotic – e.g., Ceftaroline, Dalbavancin, Daptomycin, Linezolid, Oritavancin, Tedizolid, Telavancin, Tigecycline, Vancomycin, Ceftobiprole</p>
	Exclusion(s)	<ul style="list-style-type: none"> - Patients with beta-lactam antibiotic allergies and MSSA - Patients who expire prior to clinical isolate results - Patients who transfer to a different hospital prior to obtaining clinical isolate results - Patients with gram-positive organisms other than SA
Goal(s) / Link to Outcome(s)		
IDSA Guideline(s)		
Supporting Evidence (Top 3 – 5)		<p>Kam KQ, Chen T, Kadri SS, et al. Epidemiology and Outcomes of Antibiotic De-escalation in Patients With Suspected Sepsis in US Hospitals. <i>Clin Infect Dis</i>. 2025;80(1):108-117. Doi:10.1093/cid/ciae591</p> <p>Cowley MC, Ritchie DJ, Hampton N, Kollef MH, Micek ST. Outcomes Associated With De-escalating Therapy for Methicillin-Resistant <i>Staphylococcus aureus</i> in Culture-Negative Nosocomial Pneumonia. <i>Chest</i>. 2019;155(1):53-59. Doi:10.1016/j.chest.2018.10.014</p> <p>De Vita E, Segala FV, Cavallin F, et al. Rapid de-escalation of anti-MRSA therapy guided by <i>S. aureus</i> nares screening for patients with pneumonia: protocol of a randomized</p>

	controlled trial (SNAP study). <i>Front Med (Lausanne)</i> . 2024;11:1416904. Published 2024 Sep 10. doi:10.3389/fmed.2024.1416904
Date posted/updated	December 2025
RxNorm RxCUI Codes	Vancomycin 11124 linezolid 193076 Daptomycin 22299 Ceftaroline 1040004 Telavancin 473837 Dalbavancin 1539239 Oritavancin 1547611 Tedizolid 1540825 Clindamycin 2582 Trimethoprim Sulfamethoxazole 10831